Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.

[Importance of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer].

Ferron G, Martinez A, Mery E, Querleu D, Thomas F, Chatelut E, Gladieff L.

Bull Cancer. 2009 Dec;96(12):1243-52. doi: 10.1684/bdc.2009.1005. Review. French.

2.

[Cytoreductive surgery and intraperitoneal hyperthermic-antiblastic therapy (HAPP) in peritoneal carcinomatosis].

Vaira M, Scuderi S, Costamagna D, Barone R, Aghemo B, Mioli PR, De Simone M.

Minerva Chir. 2002 Oct;57(5):597-605. Review. Italian.

PMID:
12370661
3.

Establishing evidence for change in ovarian cancer surgery--proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis.

Chua TC, Liauw W, Robertson G, Morris DL.

Gynecol Oncol. 2009 Oct;115(1):166-8; author reply 168-9. doi: 10.1016/j.ygyno.2009.06.010. Epub 2009 Jul 14. No abstract available.

PMID:
19604568
4.

Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma.

Helm CW, Randall-Whitis L, Martin RS 3rd, Metzinger DS, Gordinier ME, Parker LP, Edwards RP.

Gynecol Oncol. 2007 Apr;105(1):90-6. Epub 2006 Dec 14.

PMID:
17173957
5.

Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.

Deraco M, Virzì S, Iusco DR, Puccio F, Macrì A, Famulari C, Solazzo M, Bonomi S, Grassi A, Baratti D, Kusamura S.

BJOG. 2012 Jun;119(7):800-9. doi: 10.1111/j.1471-0528.2011.03207.x.

6.

Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.

Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M, Tarquini S, Di Seri M, Ciardi A, Montruccoli D, Sammartino P.

Cancer. 2008 Jul 15;113(2):315-25. doi: 10.1002/cncr.23553.

7.

Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).

Baratti D, Kusamura S, Nonaka D, Oliva GD, Laterza B, Deraco M.

Ann Surg Oncol. 2007 Oct;14(10):2790-7. Epub 2007 Jul 28.

PMID:
17661150
8.

The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.

Helm CW.

Oncologist. 2009 Jul;14(7):683-94. doi: 10.1634/theoncologist.2008-0275. Epub 2009 Jul 16. Review.

9.

Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients.

Frenel JS, Leux C, Pouplin L, Ferron G, Berton Rigaud D, Bourbouloux E, Dravet F, Jaffre I, Classe JM.

J Surg Oncol. 2011 Jan 1;103(1):10-6. doi: 10.1002/jso.21732.

PMID:
21031424
10.

Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).

Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M.

Ann Surg Oncol. 2009 Feb;16(2):463-72. doi: 10.1245/s10434-008-0219-1. Epub 2008 Dec 12.

PMID:
19082859
11.

Peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian peritoneal carcinomatosis: an argued role.

Di Giorgio A, Cardi M, Sammartino P.

Gynecol Oncol. 2010 Apr;117(1):146-7. doi: 10.1016/j.ygyno.2009.12.026. Epub 2010 Jan 22. No abstract available.

PMID:
20096922
12.

Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis.

Salvatorelli E, De Tursi M, Menna P, Carella C, Massari R, Colasante A, Iacobelli S, Minotti G.

Drug Metab Dispos. 2012 Dec;40(12):2365-73. doi: 10.1124/dmd.112.047480. Epub 2012 Sep 12.

13.

Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study.

Fagotti A, Paris I, Grimolizzi F, Fanfani F, Vizzielli G, Naldini A, Scambia G.

Gynecol Oncol. 2009 Jun;113(3):335-40. doi: 10.1016/j.ygyno.2009.03.004. Epub 2009 Apr 5.

PMID:
19345401
14.

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a case report.

Rotruck S, Wilson JT, McGuire J.

AANA J. 2014 Apr;82(2):140-3.

PMID:
24902457
15.

Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study.

de Bree E, Rosing H, Filis D, Romanos J, Melisssourgaki M, Daskalakis M, Pilatou M, Sanidas E, Taflampas P, Kalbakis K, Beijnen JH, Tsiftsis DD.

Ann Surg Oncol. 2008 Apr;15(4):1183-92. doi: 10.1245/s10434-007-9792-y. Epub 2008 Feb 1.

PMID:
18239973
16.

The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study.

Spiliotis J, Vaxevanidou A, Sergouniotis F, Lambropoulou E, Datsis A, Christopoulou A.

J BUON. 2011 Jan-Mar;16(1):74-9.

PMID:
21674853
17.

Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer.

Carrabin N, Mithieux F, Meeus P, Trédan O, Guastalla JP, Bachelot T, Labidi SI, Treilleux I, Rivoire M, Ray-Coquard I.

Bull Cancer. 2010 Apr;97(4):E23-32. doi: 10.1684/bdc.2010.1063.

18.

A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer.

Chiva LM, Gonzalez-Martin A.

Gynecol Oncol. 2015 Jan;136(1):130-5. doi: 10.1016/j.ygyno.2014.11.072. Epub 2014 Nov 28.

PMID:
25434634
19.

Technology of hyperthermic intraperitoneal chemotherapy in the United States, Europe, China, Japan, and Korea.

Esquivel J.

Cancer J. 2009 May-Jun;15(3):249-54. doi: 10.1097/PPO.0b013e3181a58e74. Review.

PMID:
19556912
20.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial.

Deraco M, Kusamura S, Virzì S, Puccio F, Macrì A, Famulari C, Solazzo M, Bonomi S, Iusco DR, Baratti D.

Gynecol Oncol. 2011 Aug;122(2):215-20. doi: 10.1016/j.ygyno.2011.05.004. Epub 2011 Jun 12.

PMID:
21665254

Supplemental Content

Support Center